[ad_1]
The immunological effects were different according to the dose of the vaccine, but they showed confidence
“It will be effective against corona strains” British health authorities are examining whether to approve emergency use
The CEO of AstraZeneca, a multinational pharmaceutical company based in London, United Kingdom, was confident in the success of the new vaccine against coronavirus infection (Corona 19) developed with the University of Oxford on the 27th (local time) .
Pascal Sorio (61), executive editor of the Daily The Times, told The Times’ Sunday Times that, like other competitors, “I think we have discovered a formula for success that can benefit from taking the vaccine twice.
In an interview conducted by Burns while staying at his home in Sydney, Australia, he said that “100% of the infection is preventable” and “cannot be said in detail because it will release a vaccine at some point”.
He said researchers say their vaccine will be effective against the corona 19 strain that has recently spread from the UK.
When asked about the efficacy of the vaccine against the COVID-19 strain, CEO Sorio added: “I think the vaccine will be effective until now” adding: “But I will continue to research and test because I am not sure.”
The Corona 19 strain virus, first discovered in southern England, UK, is known to be up to 70% stronger than the existing virus, and is now spreading across Europe and spreading to the Middle East, Asia , Australia and North America.
The COVID-19 vaccine developed by AstraZeneca and the University of Oxford showed different immunity effects depending on the dose as a result of an interim analysis of the phase 3 clinical trial.
When the full dose of the vaccine was given twice, the prevention rate was only 62.1%, but when the first half of the dose and the second full dose were given, the prevention rate increased to 90.0% .
The average prevention rate is 70.4%, which is less effective than the vaccine developed by Pfizer, a US pharmaceutical company, and Bioentech, Germany (95%), and a vaccine developed by the US pharmaceutical company Modena (94, 5%).
CEO Sorio admitted that he was “shocked” when he first discovered that the immune effects were different depending on the dose of the vaccine, and confessed: “I knew for sure that people might be a little disappointed.
“Of course, I wish the results were simpler, but because they met the standards set by regulatory authorities around the world, I evaluated them positively,” he added. “I didn’t expect a storm to come.”
When AstraZeneca and the University of Oxford announced their interim clinical results last month, criticism emerged over the difference in efficacy based on dosage, and the share price fell 3.8%.
CEO Sorio said AstraZeneca and the University of Oxford are currently working on a new version of the vaccine. I hope it is not necessary, but it is because preparations such as the corona 19 virus variant that appeared in South Africa are necessary.
On the 21st, AstraZeneca and the University of Oxford applied for the emergency use of the Corona 19 vaccine manufactured by both companies to the UK Medicines and Healthcare Products Regulatory Authority (MHRA).
MHRA may announce whether the vaccine is approved for emergency use starting this week, according to foreign outlets such as Bloomberg News.
Compared to other vaccines, the AstraZeneca-Oxford vaccine is cheaper and can be stored in a general refrigerator, so the transport process is not difficult.
Yunhap news
[ad_2]
